{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:12:56Z","timestamp":1791465176902,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.canlet.2012.03.034","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T01:37:06Z","timestamp":1333503426000},"page":"77-87","source":"Crossref","is-referenced-by-count":73,"title":["Overcoming acquired resistance to letrozole by targeting the PI3K\/AKT\/mTOR pathway in breast cancer cell clones"],"prefix":"10.1016","volume":"323","author":[{"given":"Andrea","family":"Cavazzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara A.","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fumarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"La Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinda","family":"Airoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta R.","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricla","family":"Galetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tramonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Galvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley-Ann","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Andreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Petronini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2012.03.034_b0005","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.03.034_b0010","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2012.03.034_b0015","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.3816\/CBC.2009.s.003","article-title":"Enhancing the efficacy of hormonal agents with selected targeted agents","volume":"9","author":"Johnston","year":"2009","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2012.03.034_b0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsbmb.2007.05.008","article-title":"Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells","volume":"106","author":"Yue","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2012.03.034_b0025","doi-asserted-by":"crossref","first-page":"30458","DOI":"10.1074\/jbc.M305226200","article-title":"Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation","volume":"278","author":"Martin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2012.03.034_b0030","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0035","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1158\/1078-0432.CCR-04-2402","article-title":"Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer","volume":"11","author":"Boulay","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jsbmb.2005.04.004","article-title":"Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance","volume":"95","author":"Johnston","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2012.03.034_b0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1677\/erc.1.00778","article-title":"Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy","volume":"11","author":"Nicholson","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2012.03.034_b0050","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/onc.2010.333","article-title":"Biological reprogramming in acquired resistance to endocrine therapy of breast cancer","volume":"29","author":"Aguilar","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.03.034_b0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","article-title":"AKT-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling","volume":"18","author":"Beeram","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2012.03.034_b0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-009-0714-5","article-title":"Synergistic activity of letrozole and sorafenib on breast cancer cells","volume":"124","author":"Bonelli","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2012.03.034_b0065","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1038\/sj.onc.1207847","article-title":"Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line","volume":"23","author":"Cavazzoni","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.03.034_b0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0003-2697(86)90314-3","article-title":"Determination of cell number in monolayer cultures","volume":"159","author":"Gillies","year":"1986","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.canlet.2012.03.034_b0075","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/sj.cdd.4401660","article-title":"Cell size reduction induced by inhibition of the mTOR\/S6K-signaling pathway protects Jurkat cells from apoptosis","volume":"12","author":"Fumarola","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2012.03.034_b0080","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0076-6879(91)06116-K","article-title":"Assay of aromatase activity","volume":"206","author":"Lephart","year":"1991","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.canlet.2012.03.034_b0085","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1158\/0008-5472.CAN-05-1208","article-title":"Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function","volume":"65","author":"Patel","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0090","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/1078-0432.CCR-07-1046","article-title":"Down-regulation of phosphatidylinositol 3\u2032-kinase\/AKT\/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer","volume":"14","author":"Generali","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0095","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","article-title":"Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients","volume":"24","author":"Bottini","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.03.034_b0100","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.tiv.2007.03.003","article-title":"A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model","volume":"21","author":"Goldoni","year":"2007","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.canlet.2012.03.034_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-6-69","article-title":"A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells","volume":"6","author":"Sam","year":"2007","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2012.03.034_b0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1023\/A:1006512018609","article-title":"Alphav integrins mediate adhesion and migration of breast carcinoma cell lines","volume":"16","author":"Wong","year":"1998","journal-title":"Clin. Exp. Metast."},{"key":"10.1016\/j.canlet.2012.03.034_b0115","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2012.03.034_b0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2012.03.034_b0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsbmb.2007.05.020","article-title":"New experimental models for aromatase inhibitor resistance","volume":"106","author":"Chen","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2012.03.034_b0130","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-04-4502","article-title":"Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole","volume":"65","author":"Jelovac","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0135","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2009.10.011","article-title":"Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines","volume":"118","author":"Masri","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2012.03.034_b0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-007-0054-5","article-title":"The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and resistant breast cancer xenografts","volume":"2","author":"Behrens","year":"2007","journal-title":"Targ. Oncol."},{"key":"10.1016\/j.canlet.2012.03.034_b0145","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant AKT Activity","volume":"10","author":"deGraffenried","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0150","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cub.2008.07.078","article-title":"Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation","volume":"18","author":"Carriere","year":"2008","journal-title":"Curr. Biol."},{"key":"10.1016\/j.canlet.2012.03.034_b0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2012.03.034_b0160","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1073\/pnas.0405659101","article-title":"Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase","volume":"101","author":"Roux","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2012.03.034_b0165","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1677\/erc.1.01006","article-title":"Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases\/oestrogen receptor cross-talk revealed in new MCF-7X model","volume":"12","author":"Staka","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2012.03.034_b0170","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1677\/erc.1.01018","article-title":"Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity","volume":"12","author":"Santen","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2012.03.034_b0175","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/0008-5472.CAN-04-4092","article-title":"The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation","volume":"65","author":"Sabnis","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0180","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr2611","article-title":"Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole","volume":"12","author":"Miller","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0185","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/onc.2010.463","article-title":"MicroRNA-101-mediated AKT activation and estrogen-independent growth","volume":"30","author":"Sachdeva","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.03.034_b0190","first-page":"S107","article-title":"Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer [Abstract]","volume":"106","author":"Baselga","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2012.03.034_b0195","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0200","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cbt.12.6.16397","article-title":"Augmentation of NVP-BEZ235\u2019s anticancer activity against human lung cancer cells by blockage of autophagy","volume":"12","author":"Xu","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2012.03.034_b0205","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0210","doi-asserted-by":"crossref","first-page":"22299","DOI":"10.1073\/pnas.0905152106","article-title":"Specific apoptosis induction by the dual PI3K\/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells","volume":"106","author":"Brachmann","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2012.03.034_b0215","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/bcr2833","article-title":"Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer","volume":"13","author":"Sanchez","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2012.03.034_b0220","doi-asserted-by":"crossref","unstructured":"C. Brunner-Kubath, W. Shabbir, V. Saferding, R. Wagner, C.F. Singer, P. Valent, W. Berger, B. Marian, C.C. Zielinski, M. Grusch, T.W. Grunt, The PI3 kinase\/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat (2010, in press).","DOI":"10.1007\/s10549-010-1232-1"},{"key":"10.1016\/j.canlet.2012.03.034_b0225","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/0008-5472.CAN-08-4450","article-title":"PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer","volume":"69","author":"Crowder","year":"2009","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512002170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512002170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T16:36:55Z","timestamp":1572021415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383512002170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0304383512002170"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2012.03.034","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}